July 09, 2026 01:36 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Dalal Street bleeds! Sensex tanks over 1,600 points after Trump declares Iran ceasefire 'over' | 'It's over': Trump says on ceasefire with Iran | PM Modi visits 1,000-year-old Prambanan Temple in Indonesia, shares majestic aerial view of the holy site | Baruipur minor rape-murder case: Key accused Pravash Mondal killed in encounter | 'We have been cheated': Egypt coach slams refereeing after Argentina match sparks controversy | From 0-2 to victory! Argentina stage miraculous comeback amid referee drama to crush Egypt's World Cup dream | Amid outrage over Baruipur, another minor girl allegedly raped in West Bengal | Kerala rain fury: 2 dead, 10 feared trapped as massive Wayanad landslide triggers rescue race | Rick Scott revives Bin Laden issue, questions Pakistan's credibility as Iran mediator | Mbappé vs Paraguayan Senator: Ugly World Cup spat spirals into international controversy

Philippines healthcare providers administer vaccine approved for prevention of Dengue

| | Feb 23, 2016, at 05:00 am
Kolkata/Lyon, Feb 22 (IBNS): Sanofi Pasteur, the vaccines division of Sanofi, announced on Monday that vaccinations with Dengvaxia have commenced in the Philippines following official receipt of the first shipment of the vaccine earlier this month.
Dengvaxia, a tetravalent dengue vaccine, was approved in the Philippines on 22 December 2015 for the prevention of disease caused by all four Dengue types in individuals from 9-45 years of age living in endemic areas. 
 
The vaccine is administered in three doses given over a one-year period. Asia bears 70% of dengue fever burden globally with an estimated 67 million people being sickened by the disease annually. 
 
In the Philippines alone, over 110,000 people on average get Dengue every year. Asian endemic countries spend an estimated 6.5 billion USD annually in both direct medical and indirect costs due to Dengue.
 
“This is truly a great moment in the history of vaccinology,” states Guillaume Leroy, Vice-President of Dengue Vaccine, Sanofi Pasteur. “Dengvaxia’s availability for administration by healthcare providers in the Philippines, to be followed closely by the initiation of a public sector immunization program in the country is a landmark event for global Dengue prevention and a great achievement for the people of the Philippines.”
 
Medical Societies in the Philippines held a media event in Manila earlier this month to welcome receipt of the first shipment of Dengvaxia to the country.
 
In attendance, Dr. Rose Capeding, chief of the Research Institute for Tropical Medicine’s department of microbiology, noted that the Philippines participated in all three phases of the clinical development of the vaccine and that healthcare providers there were delighted to be able to begin vaccinating against dengue, which continues to pose a major public health threat to the nation.
 

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.